Friday, March 31, 2023
- 2:30PM-3:00PM
-
Abstract Number: 006
Implementation of Automated Depression Screening in Patients with Lupus in a Tertiary Pediatric Rheumatology Clinic
Plenary Abstracts Session II- 2:30PM-3:00PM
-
Abstract Number: 005
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study
Plenary Abstracts Session II- 4:30PM-5:00PM
-
Abstract Number: 028
Achieving Medication-Free Remission in Juvenile Dermatomyositis
Poster Breakout 4 - JDM & Scleroderma: Clinical & Therapeutic Aspects- 4:30PM-5:00PM
-
Abstract Number: 029
Cardiac Magnetic Resonance Imaging in Children with Systemic Lupus Erythematosus and Scleroderma Spectrum Disorders: A Single Center Experience
Poster Breakout 4 - JDM & Scleroderma: Clinical & Therapeutic Aspects- 4:30PM-5:00PM
-
Abstract Number: 032
From Bedside to Bench and Back: Discovery of a Novel Missense Variant in NLRP3 Causing Atypical Cryopyrin-Associated Periodic Syndromes with Hearing Loss as the Primary Presentation, Responsive to Anti-IL1 Therapy
Poster Breakout 5 - Autoinflammatory/Vasculitis: STAT3, NLRP3, KD and MIS-C- 4:30PM-5:00PM
-
Abstract Number: 040
HLA DRB1*15 and Eosinophilia Are Common Among Patients with Systemic Juvenile Idiopathic Arthritis
Poster Breakout 6 - Systemic JIA: Genomics, Transcriptomics & Disease States- 4:30PM-5:00PM
-
Abstract Number: 038
HLA-DRB1*15 Alleles in Systemic Juvenile Idiopathic Arthritis with Lung Disease and Macrophage Activation Syndrome in Italy
Poster Breakout 6 - Systemic JIA: Genomics, Transcriptomics & Disease States- 4:30PM-5:00PM
-
Abstract Number: 027
Identifying and Understanding JDM in Africa: A Survey of Rheumatology Care Providers from Africa
Poster Breakout 4 - JDM & Scleroderma: Clinical & Therapeutic Aspects- 4:30PM-5:00PM
-
Abstract Number: 030
International Validation of the Total Morbidity Score for Juvenile Localized Scleroderma: 2023 Update
Poster Breakout 4 - JDM & Scleroderma: Clinical & Therapeutic Aspects- 4:30PM-5:00PM
-
Abstract Number: 033
Kawasaki Disease (KD) Criteria Fulfillment and Associated Outcomes in Multisystem Inflammatory Syndrome in Children (MIS-C)
Poster Breakout 5 - Autoinflammatory/Vasculitis: STAT3, NLRP3, KD and MIS-C- 4:30PM-5:00PM
-
Abstract Number: 031
Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants
Poster Breakout 5 - Autoinflammatory/Vasculitis: STAT3, NLRP3, KD and MIS-C- 4:30PM-5:00PM
-
Abstract Number: 026
Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument in a Juvenile Systemic Sclerosis Cohort
Poster Breakout 4 - JDM & Scleroderma: Clinical & Therapeutic Aspects- 4:30PM-5:00PM
-
Abstract Number: 036
Predictive Factors of Long-lasting Remission Following Anakinra Withdrawal in Patients with Systemic Juvenile Idiopathic Arthritis After Achievement of Clinical Inactive Disease
Poster Breakout 6 - Systemic JIA: Genomics, Transcriptomics & Disease States- 4:30PM-5:00PM
-
Abstract Number: 035
SARS-CoV-2 Vaccination of Children with a History of Multisystem Inflammatory Syndrome